Researchers are testing the impact of giving the monoclonal antibody weekly rather than every 28 days and
in combination with other therapies.
A safe attenuated replicating virus to combat cancer as a single agent or
in combination with other therapies.
Research in Australia, Europe and North America has proven its efficacy as a stand - alone treatment and
in combination with other therapies.